Back to News

Guggenheim lowers Enliven Therapeutics stock price target to $78

Article content is unavailable (received only '403'), so no news-specific financial details, events, or figures could be extracted for analysis.

Analysis

Article content is unavailable (received only '403'), so no news-specific financial details, events, or figures could be extracted for analysis.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

More News